This site is intended for Healthcare Professionals only

New drug for eosinophilic oesophagitis

Health & NHS bookmark icon off

New drug for eosinophilic oesophagitis

Eosinophilic oesophagitis, an inflammatory condition that is probably caused by food allergies or other environmental triggers, can be misdiagnosed as gastrooesophageal reflux disease. In adults, for example, symptoms include dysphagia, bolus obstruction and chest pain that is related to swallowing, heartburn and regurgitation.

Recently Dr Falk Pharma UK launched Jorveza, an orodispersible tablet containing budesonide which, the company says, “is specifically designed to deliver directly to the inflammation within the oesophageal mucosa”. The company describes Jorveza as “the first globally licensed drug” approved for eosinophilic oesophagitis.

Copy Link copy link button

Health & NHS

Share: